Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CTSB | P07858 | 4/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CTSH | P09668 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670737 | 1.00 | CTSK (0.53) | CTSKCTSLCTSBSYKMAPT | |
| SCHEMBL8311926 | 0.92 | CTSK (0.56) | CTSKCTSLCTSBSYKMAPT | |
| SCHEMBL142265 | 0.91 | SYK (0.53) | CTSKCTSLCTSBSYKMAPT | |
| SCHEMBL6356636 | 0.88 | CTSK (0.58) | CTSKCTSLCTSBCTSHSIRT2 | |
| SCHEMBL699601 | 0.85 | MAPT (0.61) | CTSKCTSLCTSBSYKMAPT | |
| SCHEMBL12247705 | 0.85 | MAPT (0.61) | CTSKCTSLCTSBSYKMAPT | |
| SCHEMBL2073840 | 0.85 | SIRT2 (0.61) | CTSLSYKMAPTSIRT2SIRT1 | |
| SCHEMBL17183393 | 0.85 | SIRT2 (0.61) | CTSLSYKMAPTSIRT2SIRT1 | |
| SCHEMBL2062558 | 0.84 | SYK (0.55) | CTSKCTSLCTSBSYK | |
| SCHEMBL2061787 | 0.84 | SYK (0.55) | CTSKCTSLCTSBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914589-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S P A (IT) | 2017-08-30 | — | — | EP | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
| EP-2914589-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - Science Park S.p.A. (IT) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | CTSK 1133/4885CTSL 1222/4885CTSB 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.